Cite
HARVARD Citation
Kawada, J. et al. (n.d.). P-180A phase 2 study of capecitabine plus oxaliplatin therapy (XELOX) for patients with inoperable/advanced gastric cancer who were resistant/intolerable to fluoropyrimidine, CDDP, taxane, and CPT-11 (OGSG1403). Annals of oncology. p. . [Online].